GLP-1 receptor agonists

Cardiovascular outcomes, non-diabetic indications, safety signals.

Semaglutide, tirzepatide, and next-gen GLP-1/GIP agonists are reshaping obesity, CV risk, NAFLD, and even neuropsychiatric research. Relaylit keeps clinicians current on new trials, off-target effects, and emerging indications.

Example brief

"GLP-1 receptor agonists beyond diabetes: obesity, heart failure, NAFLD. RCTs and meta-analyses only."

Paste this into your Relaylit profile and tweak. First digest arrives within hours.

Where Relaylit searches for this topic

PubMed

35M+ biomedical citations from MEDLINE, life-science journals, and online books.

About PubMed →

Europe PMC

42M+ life science citations, including preprints and full-text open-access papers.

About Europe PMC →

Crossref

155M+ records covering journals, conference proceedings, books, and preprints with DOIs.

About Crossref →

Ready to track this?

Your first glp-1 receptor agonists digest lands this week.

Start free